1526 related articles for article (PubMed ID: 17255138)
1. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
2. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
[TBL] [Abstract][Full Text] [Related]
3. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
[TBL] [Abstract][Full Text] [Related]
5. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
[TBL] [Abstract][Full Text] [Related]
6. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
Huang WF; Hsiao FY; Wen YW; Tsai YW
Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
[TBL] [Abstract][Full Text] [Related]
8. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study.
Rahme E; Nedjar H; Bizzi A; Morin S
Aliment Pharmacol Ther; 2007 Nov; 26(10):1387-98. PubMed ID: 17892525
[TBL] [Abstract][Full Text] [Related]
9. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
Roumie CL; Choma NN; Kaltenbach L; Mitchel EF; Arbogast PG; Griffin MR
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1053-63. PubMed ID: 19637402
[TBL] [Abstract][Full Text] [Related]
10. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
[TBL] [Abstract][Full Text] [Related]
11. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?
Rahme E; Barkun AN; Toubouti Y; Scalera A; Rochon S; Lelorier J
Arthritis Rheum; 2007 Jun; 57(5):748-55. PubMed ID: 17530673
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
[TBL] [Abstract][Full Text] [Related]
13. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S
Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
[TBL] [Abstract][Full Text] [Related]
14. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
[TBL] [Abstract][Full Text] [Related]
15. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
Patterson MK; Castellsague J; Walker AM
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
17. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
18. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada.
Rahme E; Barkun A; Nedjar H; Gaugris S; Watson D
Am J Gastroenterol; 2008 Apr; 103(4):872-82. PubMed ID: 18371130
[TBL] [Abstract][Full Text] [Related]
19. The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.
Warner JJ; Weideman RA; Kelly KC; Brilakis ES; Banerjee S; Cunningham F; Harford WV; Kazi S; Little BB; Cryer B
J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):252-60. PubMed ID: 18787084
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with celecoxib and rofecoxib utilization.
Rawson NS; Nourjah P; Grosser SC; Graham DJ
Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]